IMITREX Tablets should
not be given to patients with history, symptoms, or signs of ischemic
cardiac, cerebrovascular, or peripheral vascular syndromes.
patients with other significant underlying cardiovascular diseases
should not receive IMITREX Tablets.
Ischemic cardiac syndromes include,
but are not limited to, angina pectoris of any type (e.g., stable
angina of effort and vasospastic forms of angina such as the Prinzmetal
variant), all forms of myocardial infarction, and silent myocardial
Cerebrovascular syndromes include, but are not limited to,
strokes of any type as well as transient ischemic attacks.
vascular disease includes, but is not limited to, ischemic bowel disease
Because IMITREX Tablets may increase blood pressure,
they should not be given to patients with uncontrolled hypertension.Concurrent administration
of MAO-A inhibitors or use within 2 weeks of discontinuation
of MAO-A inhibitor therapy is contraindicated (see CLINICAL PHARMACOLOGY:
Drug Interactions and PRECAUTIONS: Drug Interactions).
should not be administered to patients with hemiplegic or basilar
IMITREX Tablets and any ergotamine-containing or ergot-type medication
(like dihydroergotamine or methysergide) should not be used within
24 hours of each other, nor should IMITREX and another 5-HT1 agonist.IMITREX Tablets are contraindicated in patients
with hypersensitivity to sumatriptan or any of their components.IMITREX Tablets
are contraindicated in patients with severe hepatic impairment.
-- An indication that a person has a condition or disease. Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain.
-- Objective evidence of disease perceptible to the examining physician.
-- A symptom complex of unknown etiology, that is characteristic of a particular abnormality.
-- Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
-- The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.
SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE
-- Angina pectoris which has not recently changed in frequency, duration or intensity. Stable angina pectoris is relieved by rest or administration or oral, sublingual or transdermal antianginal medications.
-- NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
-- sudden neurologic impairment due to a cerebrovascular disorder, either an arterial occlusion or an intracranial hemorrhage.
Transient Ischemic Attack
-- Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
Peripheral Vascular Diseases
-- Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.
Gastrointestinal tract vascular insufficiency
-- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.